Due to the pandemic, Edward Lifesciences' (EW) sales were not as robust in 1H20 compared to recent quarters/years. As a result, management pulled back their guidance but the stock price remained fairly steady before its recent increase higher. Now, the stock price is up ~13% over a 1-year period. This is interesting because management has scaled back expectations for FY20, but provided solid cadence for the back end of the year. Right now, especially with the less than stellar revenue growth in 1H20, the stock is priced for perfection. This article will examine what EW